These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36317185)

  • 1. Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial.
    Halpin DMG; Kendall R; Shukla S; Martin A; Shah D; Midwinter D; Beeh KM; Kocks JWH; Jones PW; Compton C; Risebrough NA; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():2745-2755. PubMed ID: 36317185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial.
    Ismaila AS; Risebrough N; Schroeder M; Shah D; Martin A; Goodall EC; Ndirangu K; Criner G; Dransfield M; Halpin DM; Han MK; Lomas DA
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2681-2695. PubMed ID: 31819401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK.
    Kendall R; Martin AA; Shah D; Shukla S; Compton C; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2023; 18():1815-1825. PubMed ID: 37636901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
    Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
    Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States.
    Bogart M; Bengtson LGS; Johnson MG; Bunner SH; Gronroos NN; DiRocco KK
    Int J Chron Obstruct Pulmon Dis; 2024; 19():97-110. PubMed ID: 38226396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective.
    Schroeder M; Benjamin N; Atienza L; Biswas C; Martin A; Whalen JD; Izquierdo Alonso JL; Riesco Miranda JA; Soler-Cataluña JJ; Huerta A; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2020; 15():1621-1632. PubMed ID: 32764908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-term clinical and economic benefits of treating advanced COPD patients with single-inhaler triple therapy in Quebec, Canada - The IMPACT trial.
    Risebrough NA; Mursleen S; Ndirangu K; Shah D; Martin A; Schroeder M; Ismaila AS
    Respir Med; 2024 Sep; 231():107694. PubMed ID: 38844004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
    Kato M; Tomii K; Hashimoto K; Nezu Y; Ishii T; Jones CE; Kilbride S; Gross AS; Clifton CS; Lipson DA
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2849-2861. PubMed ID: 31839705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial.
    Paly VF; Vallejo-Aparicio LA; Martin A; Izquierdo JL; Riesco JA; Soler-Cataluña JJ; Abreu C; Biswas C; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():3097-3109. PubMed ID: 36561129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
    Hanania NA; Mannino DM; Criner GJ; Dransfield MT; Han MK; Jones CE; Kilbride S; Lomas DA; Martin N; Martinez FJ; Singh D; Wise RA; Halpin DMG; Lima R; Lipson DA
    Chest; 2021 Mar; 159(3):985-995. PubMed ID: 33031829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study.
    Rothnie KJ; Wood RP; Czira A; Banks VL; Camidge LJ; Massey OKI; Seif M; Compton C; Sharma R; Halpin DMG; Ismaila AS; Vogelmeier CF
    BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38772900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial.
    Panettieri RA; Camargo CA; Cheema T; El Bayadi SG; Fiel S; Vila TM; Jain RG; Midwinter D; Thomashow B; Ludwig-Sengpiel A; Lipson DA
    Int J Chron Obstruct Pulmon Dis; 2022; 17():2043-2052. PubMed ID: 36072608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
    Marín JM; Mateos L; Roldán J; Echave-Sustaeta JM; Pascual-Guardia S; Pardo MV; Velasco B; Jones CE; Kilbride S; Lipson DA
    Ther Adv Respir Dis; 2020; 14():1753466620963021. PubMed ID: 33121372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany.
    Beeh KM; Rothnie KJ; Claussen J; Hardtstock F; Knapp RK; Wilke T; Czira A; Compton C; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2024; 19():945-956. PubMed ID: 38646606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis.
    Bardsley S; Criner GJ; Halpin DMG; Han MK; Hanania NA; Hill D; Lange P; Lipson DA; Martinez FJ; Midwinter D; Siler TM; Singh D; Wise RA; van Zyl-Smit RN; Berkman N
    Respir Med; 2022 Dec; 205():107040. PubMed ID: 36470149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study.
    Vogelmeier CF; Beeh KM; Schultze M; Kossack N; Richter LM; Claussen J; Compton C; Noorduyn SG; Ismaila AS; Requena G
    Int J Chron Obstruct Pulmon Dis; 2024; 19():1835-1848. PubMed ID: 39140078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
    Day NC; Kumar S; Criner G; Dransfield M; Halpin DMG; Han MK; Jones CE; Kaisermann MC; Kilbride S; Lange P; Lomas DA; Martin N; Martinez FJ; Singh D; Wise R; Lipson DA
    Respir Res; 2020 Jun; 21(1):139. PubMed ID: 32503599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial.
    Gabrio A; Gunsoy NB; Baio G; Martin A; Paly VF; Risebrough N; Halpin DMG; Singh D; Wise RA; Han MK; Martinez FJ; Criner GJ; Martin N; Lipson DA; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1633-1642. PubMed ID: 35915738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model.
    Shukla S; Shah D; Martin A; Risebrough NA; Kendall R; Vogelmeier CF; Boucot I; Tombs L; Bjermer L; Jones PW; Kerwin E; Compton C; Maltais F; Lipson DA; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2021; 16():3105-3118. PubMed ID: 34916789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.